



CryoLife Announces Release Date and Teleconference Call Details for 2nd Quarter 2001 Revenues and Earnings Results

July 9, 2001

ATLANTA, Jul 9, 2001 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, announced today that 2nd quarter revenues and earnings will be released on Tuesday, July 17, 2001.

The Company also announced that following the release of financial results, a teleconference will be held promptly at 11:15 a.m. Eastern Time July 17, 2001 hosted by Steven G. Anderson, CryoLife President and Chief Executive Officer.

Individuals interested in listening to the live teleconference may do so by calling 973-633-1010 a few minutes prior to 11:15 a.m. on July 17, 2001. No identification number is required. Those interested in listening to a replay of the teleconference may do so by calling (toll free) 877-519-4471 or 973-341-3080. The identification number for the replay is 2690903. The replay will be available July 17 through July 20, 2001.

Founded in 1984, CryoLife, Inc., is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is approved as an adjunct for acute thoracic aortic dissections under HDE regulations in the United States and is CE marked in the European Community and approved in Canada and Australia for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve, the world's first tissue-engineered heart valve replacement and the CryoLife-O'Brien(R) and CryoLife-Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community. The human heart valves and vascular grafts processed by CryoLife using the SynerGraft technology are distributed in the U.S. under the trade names of CryoValve(R)SG and CryoVein(R)SG, respectively.

For additional information about the company, visit CryoLife's web site: <http://www.cryolife.com>

CONTACT: D. Ashley Lee, Vice President, Chief Financial Officer of
Cryolife, Inc., 800-438-8285

MAKE YOUR OPINION COUNT - [Click Here](#)
<http://tbutton.prnewswire.com/prn/11690X55019837>

SOURCE CryoLife, Inc.

CONTACT: D. Ashley Lee, Vice President, Chief Financial Officer of
Cryolife, Inc., 800-438-8285